Skip to main content
SpringerLink
Log in

New Biomarkers as Prognostic Factors for Cardiovascular Complications in Type 2 Diabetic Patients

  • Original Research Article
  • Published:
Indian Journal of Clinical Biochemistry Aims and scope Submit manuscript

Abstract

This study was initiated to explore some novel biomarkers like pro-inflammatory markers (chemerin and visfatin) and anti-inflammatory marker (omentin-1) as prognostic factors for cardiovascular complications in type 2 diabetic patients. Forty diabetic patients without cardiovascular disease, 40 diabetic patients with cardiovascular disease and twenty healthy control counterparts were included in this study. Serum chemerin, omentin-1 and visfatin levels were quantified. Receiver operating characteristic curve analysis was done to identify the cut off value for each marker. The mean serum level of chemerin was 57.65 ± 15.69 ng/l in diabetic patients versus 93.97 ± 26.62 ng/l for the cardio-diabetic ones (P < 0.0001). The mean serum level of omentin-1 was 8.77 ± 1.53 ng/ml in diabetic patients versus 1.76 ± 0.96 ng/ml for the cardio-diabetic ones (P < 0.0001). The mean level of visfatin was 1.44 ± 0.71 ug/l in diabetic patients versus 3.92 ± 3.32 ug/l for the cardio-diabetic ones (P < 0.0001). Chemerin and Visfatin levels were significantly enhanced in the cardio-diabetic patients with increasing C-reactive protein (CRP), triglycerides (TG), fasting blood glucose (FBG), micro-albumin and cholesterol. Omentin-1 level was significantly reduced in the cardio-diabetic patients with increasing CRP, TG, FBG, and cholesterol. It was observed that the area under curve for chemerin, omentin-1and visfatin was 0.877, 0.998 and 0.735, respectively. In conclusion, this study evidences that the measuring serum levels of chemerin, omentin-1 and visfatin may help in the prognosis of cardiovascular complications in type 2 diabetic patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. International Diabetes Federation. IDF diabetes atlas. 7th ed. Brussels: International Diabetes Federation; 2015.

    Google Scholar 

  2. Wolfs MGM, Hofker MH, Wijmenga C, van Haeften TW. Type 2 diabetes mellitus: new genetic insights will lead to new therapeutics. Curr Genomics. 2009;10(2):110e8.

    Article  Google Scholar 

  3. Fox Caroline S, Golden Sherita H, Anderson C, Bray A, Burke E, de Boer H, et al. Update on preventation of cardiovascular disease in adults with type 2diabetes mellitus in light of recent evidence: a scientific statement from American Heart Association and American Diabetes Association. Cardiovasc Dis Diabetes Diabetes Care. 2015;38(9):1777–803.

    CAS  Google Scholar 

  4. Gijs HG, Ellen EB. Adipose tissue dysfunction and impaired metabolic health in human obesity: a matter of oxygen? Front Endocrinol. 2015;6:55.

    Google Scholar 

  5. Yan Q, Zhang Y, Hong J, Gu W, Dai M, Shi J, et al. The association of serum chemerin level with risk of coronary artery disease in Chinese adults. Endocrine. 2012;41(2):281e–8.

    Article  Google Scholar 

  6. Yang R, Xu A, Pray J, Hu H, Jadhao S, Hansen B. Cloning of omentin, a new adipocytokine from omental fat tissue in humans. Diabetes. 2003;52:A1.

    Article  Google Scholar 

  7. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011;11(2):85e–97.

    Article  Google Scholar 

  8. Cohn JN. Vascular wall function as a risk marker for cardiovascular disease. J Hypertens Suppl. 1999;17:S41e–4.

    Article  Google Scholar 

  9. Cruickshank K, Riste L, Anderson SG, Wright JS, Dunn G, Gosling RG. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function? Circulation. 2002;106:2085e–90.

    Article  Google Scholar 

  10. Hatziagelaki Erifili, Herder Christian, Tsiavou Anastasia, Teichert Tom, Chounta Athina, Nowotny Peter, et al. Serum chemerin concentrations associate with beta-cell function, but not with insulin resistance in individuals with non-alcoholic fatty liver disease (NAFLD). PLoS ONE. 2015;10(5):e0124935.

    Article  Google Scholar 

  11. Moreno-Navarrete JM, Catalán V, Ortega F, Gómez-Ambrosi J, Ricart W, Frühbeck G. Circulating omentin concentration increases after weight loss. Nutr Metab (Lond). 2010;7:27.

    Article  Google Scholar 

  12. Yamawaki H, Tsubaki N, Mukohda M, Okada M, Hara Y. Omentin, a novel adipokine, induces vasodilation in rat isolated blood vessels. Biochem Biophys Res Commun. 2010;393:668–72.

    Article  CAS  Google Scholar 

  13. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005;307:426–30.

    Article  CAS  Google Scholar 

  14. Noorah Saleh A. exploration of the relationship between adipocytokines, tradition risk markers, nontraditional risk markers and anthropometric measurements in T2DM patients. J Biomed Sci Eng. 2015;8:184–200.

    Article  Google Scholar 

  15. Gualillo O, González-Juanatey JR, Lago F. The emerging role of dipokines as mediators of cardiovascular function: physiologic and clinical perspectives. Trends Cardiovasc Med. 2007;17:275–83.

    Article  CAS  Google Scholar 

  16. El-Mesallamy HO, El-Derany MO, Hamdy NM. Serum omentin-1 and chemerin levels are interrelated in patients with type 2 diabetes mellitus with or without ischaemic heart disease. Diabet Med. 2011;28(10):1194–200.

    Article  CAS  Google Scholar 

  17. Sell H, Laurencikiene J, Taube A, Eckardt K, Cramer A, Horrighs A, et al. Chemerin Is a novel adipocyte-derived factor inducing insulin resistance in primary human skeletal muscle cells. Diabetes. 2009;58(12):2731–40.

    Article  CAS  Google Scholar 

  18. Yan P, Liu D, Long M, Ren Y, Pang J, Li R. Changes of serum omentin levels and relationship between omentin and adiponectin concentrations in type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 2011;119:257–63.

    Article  CAS  Google Scholar 

  19. Abd-Elbaky Atif E, Abo-ElMatty Dina M, Mesbah Noha M, Ibrahim Sherine M. Associations of serum omentin and apelin concentrations with obesity, diabetes mellitus type 2 and cardiovascular diseases in egyptian population. Endocrinol Metab Synd. 2015;4:2.

    Google Scholar 

  20. Urbanova M, Dostalova I, Trachta P, Drapalova J, Kavalkova P, Haluzikova D, et al. Serum concentrations and subcutaneous adipose tissue mRNA expression of omentin in morbid obesity and type 2 diabetes mellitus: the effect of very low caloric diet, physical activity and laparoscopic sleeve gastrectomy. Physiol Res. 2014;63:207–18.

    CAS  PubMed  Google Scholar 

  21. Takebayashi K, Suetsugu M, Wakabayashi S. Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus. Metabolism. 2007;56(4):451–8.

    Article  CAS  Google Scholar 

  22. Ying Wang and Dongying. Z. Serum chemerin levels and risk of coronary atherosclerosis in early-onset coronary artery disease of chinese population. J Am Coll Cardiol. 2014;64(16):0735–1097.

    Google Scholar 

  23. Liang Z, Yu K, Wu B, Zhong Y, Zeng Q. The elevated levels of plasma chemerin and C-reactive protein in patients with acute coronary syndrome. Chin J Cell Mol Immunol. 2015;31(7):953–6.

    CAS  Google Scholar 

  24. Wittamer V, Franssen JD, Vulcano M, Mirjolet JF, Le Poul E, Migeotte I, et al. Specific recruitment of antigenpresenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J Exp Med. 2003;198:977–85.

    Article  CAS  Google Scholar 

  25. Zhong Xia, Zhang Hai-yang, Tan Hui, Zhou Yi, Liu Fu-li, Chen Fu-qin, et al. Association of serum omentin-1 levels with coronary artery disease. Acta Pharmacol Sin. 2011;32:873–8.

    Article  CAS  Google Scholar 

  26. Kataoka Yoshiyuki, Shibata Rei, Ohashi Koji, Kambara Takahiro, Enomoto Takashi, Uemura Yusuke, et al. Omentin prevents myocardial ischemic injury through AMP-activated protein kinase- and Akt-dependent mechanisms. J Am Coll Cardiol. 2014;63:24.

    Article  Google Scholar 

  27. Zakaria E, El-Rawi H, Ghanem NS, Elsayed NM, Rashed L, El-Tony E. Serum visfatin level in egyptian diabetics with and without microvascular complications. Med J Cairo Univ. 2013;81(1):411–5.

    Google Scholar 

  28. Romacho T, Sánchez-Ferrer CF, Peiró C. Visfatin/Nampt: an adipokine with cardiovascular impact. Cairo: Hindawi Publishing Corporation Mediators of Inflammation; 2013.

    Google Scholar 

  29. Romacho T. AzcutiaV, azquez-Bella MV. Extracellular PBEF/NAMPT/visfatin activates pro-inflammatory signaling in human vascular smooth muscle cells through nicotinamide phosphoribosyltransferase activity. Diabetologia. 2009;52(11):2455–63.

    Article  CAS  Google Scholar 

  30. Pacher P, Obrosova IG, Mabley JG, Szab´o C. Role of nitrosative stress and peroxynitrite in the pathogenesis of diabetic complications. Emerging new therapeutical strategies. Curr Med Chem. 2005;12(3):267–75.

    Article  CAS  Google Scholar 

  31. Goralski KB, McCarthy TC, Hanniman EA, Zabel BA, Butcher EC, Parlee SD, Muruganandan S, Sinal CJ. Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabo-lism. J Biol Chem. 2007;282:28175–88.

    Article  CAS  Google Scholar 

  32. Tan BK, Adya R, Randeva HS. Omentin: a novel link between inflammation, diabesity, and cardiovascular disease. Trends Cardiovasc Med. 2010;20:143–8.

    Article  CAS  Google Scholar 

  33. Shibata R, Ouchi N, Kikuchi R, Takahashi R, Kataoka Y, Ohashi K. Circulating omentin is associated with coronary artery disease in men. Atherosclerosis. 2011;219:811–4.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hormones Department, National Research Centre, Dokki, Giza, Egypt

    Hanaa H. Ahmed

  2. Biochemistry Department, Faculty of Science, Helwan University, Cairo, Egypt

    Wafaa Gh. Shousha & Hatem A. El-mezayen

  3. Biochemistry Department, National Institute of Diabetes and Endocrinology, Cairo, Egypt

    Ibrahim A. Emara & Marwa E. Hassan

Authors
  1. Hanaa H. Ahmed
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wafaa Gh. Shousha
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hatem A. El-mezayen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ibrahim A. Emara
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Marwa E. Hassan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hanaa H. Ahmed.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ahmed, H.H., Shousha, W.G., El-mezayen, H.A. et al. New Biomarkers as Prognostic Factors for Cardiovascular Complications in Type 2 Diabetic Patients. Ind J Clin Biochem 35, 54–62 (2020). https://doi.org/10.1007/s12291-018-0784-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12291-018-0784-4

Keywords

Search

Navigation